In a new study led by Fox Chase Cancer Center radiation oncologist Natasha Townsend, M.D., researchers have found that Gleason scores determined by pathologists at Fox Chase Cancer Center more accurately predict the risk of recurrence than Gleason scores from referring institutions.

NEW YORK, Sept.

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- A new study in the journal Cancer shows that staging prostate cancer that has not metastasized beyond the prostate gland does predict the outcome, prognosis or risk of cancer recurrence after a radical prostatectomy.

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease.

BACKGROUND: The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients.